Hammersmith Medicines Research Ltd

Belkins
HMR is a Contract Research Organisation (CRO). We specialise in and can provide a full service for phase 1 and early phase 2 studies. Our premises are spacious (5995 m²) and have 145 beds, a sleep unit for polysomnography, facilities for volunteers, laboratories, a pharmacy, including an aseptic unit and radiopharmacy, and offices. We have over 250 staff – 10 physicians, 35 nurses or nurse graduates, and over 200 graduates or PhD. We have done over 850 studies since 1993. HMR is one of the largest early-phase CROs in Europe.

Related News

BUSINESS INSIGHTS

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

news image

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More

COVID-19 PANDEMIC: RAPID DELIVERY OF MEDICAL COUNTERMEASURES

Contract Pharma | April 03, 2020

news image

Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials such as DNA and RNA-based vaccine candidates, adjuvant platform technologies, recombinant nanoparticles, and monoclonal antibodies, to name a few. As promising therapies begin to emerge, they’ll need to be rapidly scaled up for trials and potential commercialization, which is not without its challe...

Read More

LEO LENS PHARMA EXCITED TO HAVE ITS LEAD ASSET READY FOR HUMAN CLINICAL EVALUATION

Leo Lens Pharma | June 23, 2020

news image

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clini...

Read More

PRACTICE MANAGEMENT

CITIUS PHARMACEUTICALS RECEIVES FDA RESPONSE AND GUIDANCE TO PRE-IND CONSULTATION SUBMISSION FOR MINO-WRAP

Citius Pharmaceutical | December 10, 2020

news image

Citius Pharmaceuticals, Inc. ("Citius" or the "Organization") (Nasdaq: CTXR), a strength drug organization zeroed in on creating and commercializing basic consideration drug items, declared its receipt of a composed reaction and direction from the U.S. Food and Drug Administration (FDA) Division of Anti-Infective Products to the Company's Pre-Investigational New Drug (Pre-IND) meeting demand for its Mino-Wrap preparation bundle. Through its worldwide permit concurrence wi...

Read More
news image

BUSINESS INSIGHTS

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More
news image

COVID-19 PANDEMIC: RAPID DELIVERY OF MEDICAL COUNTERMEASURES

Contract Pharma | April 03, 2020

Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials such as DNA and RNA-based vaccine candidates, adjuvant platform technologies, recombinant nanoparticles, and monoclonal antibodies, to name a few. As promising therapies begin to emerge, they’ll need to be rapidly scaled up for trials and potential commercialization, which is not without its challe...

Read More
news image

LEO LENS PHARMA EXCITED TO HAVE ITS LEAD ASSET READY FOR HUMAN CLINICAL EVALUATION

Leo Lens Pharma | June 23, 2020

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clini...

Read More
news image

PRACTICE MANAGEMENT

CITIUS PHARMACEUTICALS RECEIVES FDA RESPONSE AND GUIDANCE TO PRE-IND CONSULTATION SUBMISSION FOR MINO-WRAP

Citius Pharmaceutical | December 10, 2020

Citius Pharmaceuticals, Inc. ("Citius" or the "Organization") (Nasdaq: CTXR), a strength drug organization zeroed in on creating and commercializing basic consideration drug items, declared its receipt of a composed reaction and direction from the U.S. Food and Drug Administration (FDA) Division of Anti-Infective Products to the Company's Pre-Investigational New Drug (Pre-IND) meeting demand for its Mino-Wrap preparation bundle. Through its worldwide permit concurrence wi...

Read More